Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Diffuse Large B cell Lymphoma (DLBCL) encompasses heterogeneous subtypes, including DLBCL not otherwise specified (NOS).
• DLBCL NOS presents significant variability in morphology, clinical features, biology, and treatment response.
• Understanding the molecular underpinnings of DLBCL NOS is crucial for improving patient outcomes.

Purpose of the Study:

• To review the molecular subgroups of DLBCL NOS identified through gene expression profiling.
• To explore the signaling pathways associated with these molecular subgroups.
• To discuss the potential of biomarkers and immunohistochemistry in clinical trial design for DLBCL NOS.

Main Methods:

• Gene expression profiling to identify molecular subgroups within DLBCL NOS.
• Analysis of mutations in key genes (e.g., CD79A/B, CARD11, MYD88, TNFAIP3, EZH2, CREBBP).
• Review of existing literature on DLBCL NOS biology and biomarker research.

Main Results:

• DLBCL NOS can be classified into molecular subgroups, such as "activated B cell" and "germinal center B cell-like" (GCB).
• "Activated B cell" subgroup is associated with Nuclear Factor kB (NF-kB) pathway activation and specific gene mutations.
• "GCB" subgroup is linked to mutations in EZH2 and CREBBP.
• Biomarkers related to tumor growth and survival pathways have been identified, but require clinical validation.

Conclusions:

• Molecular subgroups of DLBCL NOS correlate with prognosis and offer insights into treatment strategies.
• Specific genetic mutations are linked to distinct molecular subtypes and signaling pathways.
• Immunohistochemistry presents a practical approach for biomarker detection and clinical trial stratification in DLBCL NOS.